(secondQuint)Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas.

 This is a multicenter, open-label, single-arm Phase 2 study of the SINE selinexor given orally to patients diagnosed with advanced SCC of the head and neck, lung, or esophagus who have experienced relapse and/or metastasis following multiple prior chemotherapy treatments (<2 lines of therapy).

 Patients will receive fixed doses of selinexor tablets twice weekly in 28-day cycles.

 Patients may continue from one cycle to the next without interruption as along as all criteria are met and no reason for discontinuation occurs.

.

 Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas@highlight

Open-label, multi-center, single-arm, Phase 2 study of oral selinexor in patients with SCC of the head and neck (HN-SCC; Cohort 1), lung (L-SCC; Cohort 2), or esophagus (E-SCC; Cohort 3) who have relapsed or have metastasis following chemotherapy.

